Ronald G Nahass MD MHCM,FIDSA

HIV/AIDS Medicine, Healthcare Associated Infections, Mycobacterial Disease

President-ID CARE, Clinical Professor of Medicine, Rutgers-RW Johnson Medical School

105 Raider BlvdSuite 101Hillsborough, NJ 08844
Phone+1 908-281-0221
Fax+1 908-281-0890

Dr. Nahass is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nahass' full profile Already have an account?

Summary

Ronald Nahass, MD, is an infectious disease specialist based in Hillsborough, NJ, with subspecialties in HIV/AIDS Medicine, Healthcare Associated Infections, and Mycobacterial Disease. He completed his medical education and residency at Rutgers Robert Wood Johnson Medical School and holds a Master's in Healthcare Leadership from Harvard School of Public Health. Dr. Nahass is currently the President of ID CARE at Infectious Disease Care. His areas of expertise include hepatitis B, hepatitis C, HIV/AIDS, and antivirals for hepatitis C and HIV. He has contributed to several publications on HIV treatment and infectious diseases and has been involved in multiple clinical trials focused on HCV and other infections. Dr. Nahass has been recognized as one of America's Top Doctors by Castle Connolly and received multiple certifications for CMS Meaningful Use.

Education & Training

Harvard T.H. Chan School of Public HealthMHCM, Healthcare Leadership, 2010 - 2012
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 1982 - 1986
Rutgers Robert Wood Johnson Medical SchoolClass of 1982
Rensselaer Polytechnic InstituteB.S., Cum Laude, 1979

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2020 - Present
NJ State Medical License 1983 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2016, 2023-2025
New York Magazine: Top Doctors Castle Connolly, 2010-2018
Top Doctors: New York Metro Area Castle Connolly

Clinical Trials

A Study of the Long-Term Outcomes of HIV-Positive Patients
COMPLETED
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
COMPLETED
PHASE2
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
COMPLETED
PHASE3

Publications & Presentations

PubMed

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled,...
Amy E Colson, Princy N Kumar, Peter J Ruane, Ploenchan Chetchotisakd, Winai Ratanasuwan
Lancet. 2026-08-12
5 citations
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Amy E Colson, Gordon E Crofoot, Peter J Ruane, Moti N Ramgopal, Alexandra W Dretler
Annals of Internal Medicine. 2026-02-01
Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS-CoV-2 Infection With and Without Diabetes.
Marshall Yuan, Andrew Wassef, Davit Sargsyan, Vahe Nersisyan, Javier Cabrera
Journal of Medical Virology. 2025-06-01

Journal Articles

Linkage to Care for Hepatitis C Virus (HCV) Among Suburban Heroin Users in New Jersey
Akyar E, Seneca KH, Akyar S, Schoefield N, Schwartz MP, Nahass RG, Emerg Infect Dis, 1/1/2016
Thorn-Induced Alternaria septic arthritis and osteomyelitis of the hand
Li Boning, Boretz R, Nahass RG, Infect Dis Clin Practice, 1/1/2016
PegInterferon/Ribavirin for 12 weeks vs Sofosbuvir + Ribavirin for 16 or 24 weeks in Genotype 3 HCV infected patients and treatment-experienced cirrhotic pacientes wit...
Foster GR, Pianko C, Cooper,A Brown A,Forton D, Nahass RG, Sofosbuvir, Hepatology, 1/1/2015

Abstracts/Posters

High efficacy of sofosbuvir/velpatasvir plus gs-9857 for 12 weeks in treatment-experienced genotype 1-6 hcv-infected patients, including those previously treated with ...
Lawitz E, Kowdley K, Curry M, Reau N, Nguyen M, Kwo P, Jacobson I, Tran T, Nahass RG, EASL, Barcelona, Spain, 1/1/2016
C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)
Dore GJ, Altice F, Litwin AH, Grebely J, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, et al, EASL, Barcelona, Spain, 1/1/2016
High efficacy of grazoprevir/elbasvir among HCV GT1, GT4, or GT6 infected patients with HIV Co Infection
Nelson M, Rockstroh J, Mallolas J, Katlama C, Nahass RG, et al, ID Week, San Diego, CA, 1/1/2015

Lectures

Hepatitits C in Clinical Practice
San Diego, CA - 1/1/2015
HIV/HCV Coinfection
1/1/2015
Infectious Disease Physicians and the Future of Healthcare
1/1/2015

Authored Content

Talking to Patients About Measles, Vitamin A and the Importance of VaccinationMarch 2025

Press Mentions

IDSA Statement on Vaccine Executive OrderAugust 10th, 2026
Senate Continuing Resolution Protects Critical Infectious Diseases Programs and Temporarily Blocks Harmful OMB Grant RuleAugust 10th, 2026
First mRNA Flu Shot Gets FDA Approval, Raising Hopes for a More Effective VaccineAugust 6th, 2026